Fundraising Fox

/Companies

Cresilon

Brooklyn, US · Delaware corporation · 4 known investors

Find your way into Cresilon

Sign up to see every warm intro you have to Cresilon

Paths you didn't know you had: your email and LinkedIn already hold routes to the Cresilon team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Sign up with Google Already have an account? Log in

Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.

Biotech Healthtech Medical Devices New Materials

Founders & leadership

IM

Isaac Miller

Isaac MillerEVP & Co-Founder

JL

Joe Landolina

Joe LandolinaCo-founder & CEO30 Under 30 2023

SL

Scott Levine

Scott Levine Chief Financial OfficerHe brings experience as a CFO at private and public companies, with expertise in financial planning and analysis in technology-enabled services, and a track record of managing financing rounds and exits.

Investors · 4

Catalio Capital Management, LPlisted by Catalio Capital Management, LPNew York

How we know: Catalio Capital Management, LP's portfolio page · Not right? Tell us

Dorm Roomlisted by Dorm RoomBrooklyn · $90K – $500K

How we know: the VCSheet dataset · Not right? Tell us

Innovating Capitallisted by Innovating CapitalNew York · $10K – $3M

How we know: the VCSheet dataset · Not right? Tell us

Also in the syndicate · 1

Paulson Investment Companylead

Funding

SEC filings, press & company announcements

$157.9M disclosed across 8 of 10 rounds · 2017–2026

Undisclosed amountSeries A-4Oct 2022
Paulson Investment Company (lead)
Source ↗

▶$29MraisedJun 2026 · 217 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Joseph LandolinaExecutive Officer, Director
Isaac MillerDirector
Scott LevineExecutive Officer

Offering amount: $29M
Amount sold: $29M
Minimum investment: $10K
Sales commissions: $3.4M
Placement agents: Paulson Investment Company, LLC
First sale: Apr 2026
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$6.7MraisedDec 2025 · 55 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Scott LevineExecutive Officer
Isaac MillerExecutive Officer, Director
Joseph LandolinaExecutive Officer, Director

Offering amount: $6.7M
Amount sold: $6.7M
Minimum investment: $25K
Sales commissions: $868.8K
Placement agents: Paulson Investment Company, LLC
First sale: Nov 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$17.2MraisedSep 2025 · 95 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Isaac MillerDirector
Joseph LandolinaExecutive Officer, Director
Scott LevineExecutive Officer

Offering amount: $34.8M
Amount sold: $17.2M
Minimum investment: $1.8K
Sales commissions: $2.2M
Placement agents: Paulson Investment Company, LLC
First sale: Apr 2025
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25MraisedJan 2025 · 237 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Joseph LandolinaExecutive Officer, Director
Isaac MillerExecutive Officer, Director
Scott LevineExecutive Officer

Offering amount: $25M
Amount sold: $25M
Minimum investment: $5K
Sales commissions: $3.1M
Proceeds to insiders: $300K
Placement agents: Paulson Investment Company, LLC
First sale: Apr 2024
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$17.2MraisedOct 2024 · 309 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Isaac MillerDirector
Scott LevineExecutive Officer
Joseph LandolinaExecutive Officer, Director

Offering amount: $38M
Amount sold: $17.2M
Minimum investment: $2.3K
Sales commissions: $2.2M
Placement agents: Paulson Investment Company, LLC
First sale: Aug 2023
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$25MraisedOct 2022 · 308 investors · Biotechnology

Rule 506(c)

Officers, directors & promoters on the filing

Joseph LandolinaExecutive Officer, Director
Isaac MillerDirector

Offering amount: $25M
Amount sold: $25M
Minimum investment: $100K
Sales commissions: $3.2M
Proceeds to insiders: $200K
Placement agents: Paulson Investment Company, LLC
First sale: Dec 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06c

Full filing on SEC EDGAR ↗

▶$24.5MraisedFeb 2021 · 170 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Joseph LandolinaExecutive Officer, Director
Isaac MillerExecutive Officer, Director

Offering amount: $45.3M
Amount sold: $24.5M
Minimum investment: $25K
Sales commissions: $2.8M
Placement agents: Paulson Investment Company, LLC
First sale: Jan 2021
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

▶$13.3MraisedJan 2018 · 55 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Isaac MillerExecutive Officer, Director
Joseph LandolinaExecutive Officer, Director

Offering amount: $19.3M
Amount sold: $13.3M
First sale: Dec 2017
Incorporated: Corporation, Delaware
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 3

AmogyAmogy develops patented ammonia cracking technology that converts ammonia into electric power for hydrogen fuel cells and engines, targeting decarbonization of heavy industries including transportation and maritime. The company offers modular ammonia-to-power systems and high-efficiency catalysts as alternatives to diesel and hydrogen fuel solutions.

WalgreensWalgreens operates a pharmacy and retail health and wellness business, offering prescription services, over-the-counter medications, health products, and photo services to consumers.

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies working in the same space as Cresilon.

In the news

Cresilon Closes $25 Million in Series A-4 Financing to Accelerate Global Expansion and Bring Revolutionary Hemostatic Gel to Human Health Marketprnewswire.com · Oct 2022

Frequently asked questions

What does Cresilon do?: Cresilon develops plant-based flowable hemostatic gel technology that controls bleeding within seconds without manual pressure, with products for veterinary care (VETIGEL) and human trauma (TRAUMAGEL). Its customers include EMS agencies, trauma hospitals, military, law enforcement, and veterinary practices.
Who founded Cresilon?: Cresilon was founded by Isaac Miller, Joe Landolina.
Who are Cresilon's investors?: Cresilon's investors include Catalio Capital Management, LP, Dorm Room, Innovating Capital.
How much funding has Cresilon raised?: Cresilon has disclosed $157.9M raised across 8 of its 10 known rounds.
Where is Cresilon headquartered?: Cresilon is headquartered in Brooklyn, US.